Clindamycin is named as an intervention in 7 current clinical trials in our France, Netherlands, Germany, Spain, Canada, USA, China, Turkey, Brazil, South Korea, Taiwan, Sweden, Japan, Singapore, Australia, Israel and Mexico registers. 5 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Leiden University Medical Center (2). The most-studied condition is Carcinoma, Non-Small-Cell Lung. The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Clindamycin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Early switch to oral antibiotic therapy in vertebral osteomyelitis: a multicentre, open-label, randomised, active control, parallel group, non-inferiority trial (sWITCH-VO)
2026-526270-17-00 · CTIS ↗ · Musculoskeletal Diseases
|
Phase 4 | Ongoing | University Of Cologne | Germany |
|
EPISSOC : Randomized controlled trial comparing an Early Pleural Irrigation strategy with Saline to the Standard of Care for the management of complicated pleural infections
2025-524697-42-00 · CTIS ↗ · Respiratory Tract Diseases
|
Phase 3 | Authorised | Centre Hospitalier Universitaire Amiens Picardie | France |
|
LIBRETTO: Stimulan™ Local Antibiotic Delivery System Versus 4-Week Systemic Antibiotic Therapy for Diabetic Foot Osteomyelitis – A Prospective, Randomized, Controlled Trial
2025-524723-52-00 · CTIS ↗ · Bacterial Infections and Mycoses
|
Phase 3 | Authorised | Pirkanmaan hyvinvointialue | Finland |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
18 single-substance products containing Clindamycin on the HPRA medicines list.
| Condition (as registered) | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 1 |
| Staphylococcus Aureus Bacteremia | 1 |
| Aortic Surgery | 1 |
| Extracorporeal Circulation | 1 |
| Endocarditis Infective | 1 |
| C. Difficile | 1 |
| C. Difficile Infection | 1 |
| Controlled Human Infection | 1 |
| Prosthetic-joint Infection | 1 |
| Infection Hip | 1 |
| Infection; Knee, Joint | 1 |
| Lactating Women on Select DOI | 1 |
| Breastfed Infants of Mothers on Select DOI | 1 |
| Lead sponsor | Trials |
|---|---|
| Leiden University Medical Center | 2 |
| Janssen Research & Development, LLC | 1 |
| University of Melbourne | 1 |
| Nantes University Hospital | 1 |
| Fundacion Clinic per a la Recerca Biomédica | 1 |
| Duke University | 1 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
7 current trials in our France, Netherlands, Germany, Spain, Canada, USA, China, Turkey, Brazil, South Korea, Taiwan, Sweden, Japan, Singapore, Australia, Israel and Mexico registers name Clindamycin as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 7 trials are recruiting: 2 with sites in France, 2 with sites in Netherlands, 1 with sites in Germany, 1 with sites in Spain, 2 with sites in Canada, 1 with sites in Sweden, 1 with sites in Japan, 1 with sites in Singapore, 1 with sites in Australia, 1 with sites in Israel and 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Leiden University Medical Center (2), Janssen Research & Development, LLC (1), University of Melbourne (1) and Nantes University Hospital (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 18 single-substance products containing Clindamycin, for example Clindamycin 150 mg Capsules, hard (Renata Pharmaceuticals (Ireland) Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 2 entries for Clindamycin: US FDA: current; US FDA: resolved. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Clindamycin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Clindamycin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Clindamycin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.